SGX-listed Singapore eDevelopment Limited’s (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. (“Impact”), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. Impact Biomedical’s transition to the Quantum research program comes on the heels of the
More
